$BMRN
BIOMARIN PHARMACEUTICAL INC

2021 Q4 Form 10-Q Financial Statement

#000104847721000032 Filed on October 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $449.8M $408.7M $476.8M
YoY Change -0.51% -14.27% 3.4%
Cost Of Revenue $119.8M $103.5M $188.8M
YoY Change -5.04% -45.16% 94.73%
Gross Profit $330.1M $305.2M $288.0M
YoY Change 1.25% 5.98% -20.91%
Gross Profit Margin 73.38% 74.67% 60.4%
Selling, General & Admin $217.6M $183.3M $179.5M
YoY Change 16.97% 2.16% 5.49%
% of Gross Profit 65.92% 60.07% 62.31%
Research & Development $161.1M $157.9M $147.1M
YoY Change 2.8% 7.36% -14.98%
% of Gross Profit 48.81% 51.73% 51.06%
Depreciation & Amortization $25.99M $11.40M $11.10M
YoY Change -5.16% 2.7% -54.2%
% of Gross Profit 7.87% 3.74% 3.85%
Operating Expenses $395.9M $341.2M $326.5M
YoY Change 10.47% 4.5% -4.83%
Operating Profit -$65.88M -$53.22M -$55.94M
YoY Change 103.33% -4.87% -1495.04%
Interest Expense -$752.0K $3.870M $9.597M
YoY Change -94.26% -59.67% 226.76%
% of Operating Profit
Other Income/Expense, Net $58.00K $8.925M $1.200M
YoY Change -98.91% 643.75% -70.0%
Pretax Income -$66.57M -$46.16M -$61.22M
YoY Change 65.61% -24.59% -723.25%
Income Tax -$4.756M -$9.666M -$846.0M
% Of Pretax Income
Net Earnings -$57.90M -$36.49M $784.8M
YoY Change -361.98% -104.65% 1325.98%
Net Earnings / Revenue -12.87% -8.93% 164.6%
Basic Earnings Per Share -$0.20 $4.33
Diluted Earnings Per Share -$315.4K -$0.20 $4.01
COMMON SHARES
Basic Shares Outstanding 183.6M shares 183.2M shares 181.1M shares
Diluted Shares Outstanding 183.2M shares 197.7M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.014B $1.079B $1.506B
YoY Change -4.83% -28.31% 108.89%
Cash & Equivalents $587.3M $617.1M $1.016B
Short-Term Investments $426.6M $462.3M $490.0M
Other Short-Term Assets $110.4M $107.8M $120.7M
YoY Change -15.0% -10.76% -4.58%
Inventory $776.7M $749.4M $700.8M
Prepaid Expenses
Receivables $373.4M $374.9M $411.7M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.274B $2.312B $2.739B
YoY Change -2.9% -15.6% 47.31%
LONG-TERM ASSETS
Property, Plant & Equipment $1.035B $1.025B $1.015B
YoY Change 0.29% 0.96% 4.72%
Goodwill $196.2M $196.2M $196.2M
YoY Change 0.0% 0.0% -0.43%
Intangibles $388.7M $388.5M $427.2M
YoY Change -6.86% -9.06% -7.71%
Long-Term Investments $507.8M $466.6M $265.1M
YoY Change 77.86% 76.02% -38.61%
Other Assets $151.8M $144.7M $119.0M
YoY Change 6.7% 21.59% 5.65%
Total Long-Term Assets $3.729B $3.666B $3.419B
YoY Change 6.36% 7.22% 26.69%
TOTAL ASSETS
Total Short-Term Assets $2.274B $2.312B $2.739B
Total Long-Term Assets $3.729B $3.666B $3.419B
Total Assets $6.003B $5.977B $6.158B
YoY Change 2.66% -2.93% 35.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $203.5M $203.3M $218.0M
YoY Change 6.3% -6.73% -6.64%
Accrued Expenses $268.9M $241.5M $231.7M
YoY Change 0.96% 4.24% 3.81%
Deferred Revenue $6.956M $9.659M $10.93M
YoY Change 4476.32% -11.63%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $377.4M
YoY Change 12480.0%
Total Short-Term Liabilities $539.8M $514.9M $854.7M
YoY Change 9.6% -39.76% 73.1%
LONG-TERM LIABILITIES
Long-Term Debt $1.079B $1.078B $1.079B
YoY Change -0.01% -0.06% 26.43%
Other Long-Term Liabilities $98.52M $103.1M $121.2M
YoY Change -13.73% -14.93% 24.43%
Total Long-Term Liabilities $98.52M $103.1M $121.2M
YoY Change -13.73% -14.93% 24.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $539.8M $514.9M $854.7M
Total Long-Term Liabilities $98.52M $103.1M $121.2M
Total Liabilities $1.733B $1.711B $2.104B
YoY Change -0.54% -18.67% 41.82%
SHAREHOLDERS EQUITY
Retained Earnings -$925.7M -$867.8M -$883.7M
YoY Change 7.44% -1.8% -49.09%
Common Stock $5.192B $5.134B $4.938B
YoY Change 3.97% 3.97% 3.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.271B $4.266B $4.054B
YoY Change
Total Liabilities & Shareholders Equity $6.003B $5.977B $6.158B
YoY Change 2.66% -2.93% 35.1%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$57.90M -$36.49M $784.8M
YoY Change -361.98% -104.65% 1325.98%
Depreciation, Depletion And Amortization $25.99M $11.40M $11.10M
YoY Change -5.16% 2.7% -54.2%
Cash From Operating Activities $11.18M $97.06M $86.20M
YoY Change -184.06% 12.6% 22.97%
INVESTING ACTIVITIES
Capital Expenditures -$44.36M -$20.36M -$20.20M
YoY Change 11.45% 0.79% -42.94%
Acquisitions
YoY Change
Other Investing Activities -$11.06M -$99.49M $126.8M
YoY Change -121.73% -178.46% 50.77%
Cash From Investing Activities -$55.42M -$119.8M $106.7M
YoY Change -603.83% -212.32% 119.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.40M -1.031M 3.300M
YoY Change -103.93% -131.24% -265.0%
NET CHANGE
Cash From Operating Activities 11.18M 97.06M 86.20M
Cash From Investing Activities -55.42M -119.8M 106.7M
Cash From Financing Activities 14.40M -1.031M 3.300M
Net Change In Cash -29.84M -23.82M 196.2M
YoY Change -91.9% -112.14% 67.98%
FREE CASH FLOW
Cash From Operating Activities $11.18M $97.06M $86.20M
Capital Expenditures -$44.36M -$20.36M -$20.20M
Free Cash Flow $55.54M $117.4M $106.4M
YoY Change 109.58% 10.36% 0.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001048477
dei Entity File Number
EntityFileNumber
000-26727
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
BioMarin Pharmaceutical Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0397820
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0397820
dei Entity Address Address Line1
EntityAddressAddressLine1
770 Lindaro Street
dei Entity Address Address Line1
EntityAddressAddressLine1
770 Lindaro Street
dei Entity Address City Or Town
EntityAddressCityOrTown
San Rafael
dei Entity Address City Or Town
EntityAddressCityOrTown
San Rafael
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
BMRN
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94901
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94901
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
506-6700
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
BMRN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
183593434 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
617143000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
649158000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
462333000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
416228000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
374937000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
448351000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
749406000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
698548000 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
107751000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
129934000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
2311570000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2342219000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
466618000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
285473000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1024787000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
144705000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
196199000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1445109000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1432150000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1032471000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
388487000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
417271000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
196199000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
142237000 USD
CY2021Q3 us-gaap Assets
Assets
5977475000 USD
CY2020Q4 us-gaap Assets
Assets
5848020000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
466711000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
492548000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
48187000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
514898000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
492548000 USD
CY2021Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1078093000 USD
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1075145000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
15204000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
60130000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
103131000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
114195000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
1711326000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
1742018000 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
183567424 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
183567424 shares
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
59495000 USD
us-gaap Inventory Write Down
InventoryWriteDown
0 USD
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
181740999 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
181740999 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
184000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
182000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5133742000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4993407000 USD
CY2021Q3 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
10225000 USD
CY2020Q4 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
9839000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10239000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16139000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-867791000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-861609000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4266149000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4106002000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5977475000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5848020000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
408742000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
476784000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1396465000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1408338000 USD
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
103537000 USD
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
188793000 USD
us-gaap Cost Of Revenue
CostOfRevenue
350765000 USD
us-gaap Cost Of Revenue
CostOfRevenue
398134000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
157869000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
147053000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
467701000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
471449000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
183333000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
179450000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
541812000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
542157000 USD
CY2021Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
17222000 USD
CY2020Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
17429000 USD
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
52648000 USD
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
48018000 USD
CY2021Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2020Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
59495000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
461961000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
532725000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1412926000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1400263000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-53219000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-55941000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-16461000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
8075000 USD
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
177000 USD
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-921000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1349000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1077000 USD
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1827000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4004000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
8737000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
13539000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
3870000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
9597000 USD
us-gaap Interest Expense
InterestExpense
11491000 USD
us-gaap Interest Expense
InterestExpense
24560000 USD
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
8925000 USD
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1239000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
11788000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1886000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46160000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-61216000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8776000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2137000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9666000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-846019000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2594000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-839138000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-36494000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
784803000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6182000 USD
us-gaap Net Income Loss
NetIncomeLoss
837001000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.63
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.39
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
183214000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
181142000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182616000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180592000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
183214000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197674000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182616000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
194959000 shares
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25316000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
765138000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20196000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
827222000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4241571000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3236679000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
-3043000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4106002000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3122381000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4266149000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
4053893000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4266149000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
4053893000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6182000 USD
us-gaap Net Income Loss
NetIncomeLoss
837001000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
82053000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77814000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3114000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
14766000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3279000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-175000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
153372000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
142125000 USD
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0 USD
us-gaap Inventory Write Down
InventoryWriteDown
75609000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-12020000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-854199000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1347000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-9082000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
6254000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1352000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1317000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-388000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-65513000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32915000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19125000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
73310000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-27029000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-32848000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
407000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5543000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7129000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-76174000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
269000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
9225000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
293356000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
98749000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66840000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83286000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
502112000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
345224000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
737144000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
369942000 USD
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
0 USD
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
67159000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
8026000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
14369000 USD
bmrn Payments To Acquire Debt Securities Available For Sale Non Marketable
PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable
0 USD
bmrn Payments To Acquire Debt Securities Available For Sale Non Marketable
PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable
8709000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
994000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
725000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-310892000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64648000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
32877000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
60268000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
44428000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
42667000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50000000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
585752000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2492000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6080000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-401000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14444000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
547273000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-35000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3145000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32015000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
578229000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
649158000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
437446000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
617143000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1015675000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
15531000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
4355000 USD
us-gaap Interest Paid Net
InterestPaidNet
6673000 USD
us-gaap Interest Paid Net
InterestPaidNet
5615000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
-7690000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
-13281000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
9389000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-508000 USD
us-gaap Nature Of Operations
NatureOfOperations
NATURE OF OPERATIONS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. Voxzogo (formerly known as vosoritide) was granted marketing approval in the European Union (EU) on August 27, 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.</span></div>
us-gaap Basis Of Accounting
BasisOfAccounting
BASIS OF PRESENTATION<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021 or any other period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the novel coronavirus (referred to as COVID-19) pandemic could continue to directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div>
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1544506000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1823000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
235000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1546094000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
617143000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
462333000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
466618000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1345801000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5069000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1350859000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
649158000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
416228000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
285473000 USD
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
75328000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
76673000 USD
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
412434000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
308286000 USD
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
261644000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
313589000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
749406000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
698548000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1724702000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1668066000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
699915000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
635595000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1024787000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1032471000 USD
CY2021Q3 us-gaap Depreciation
Depreciation
11400000 USD
us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
6200000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
661781000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
644087000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
273294000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
226816000 USD
us-gaap Depreciation
Depreciation
35700000 USD
CY2020Q3 us-gaap Depreciation
Depreciation
11100000 USD
us-gaap Depreciation
Depreciation
31100000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
388487000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
417271000 USD
CY2021Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
203321000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
191429000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
158130000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
165023000 USD
CY2021Q3 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
68329000 USD
CY2020Q4 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
65526000 USD
CY2021Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
14512000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
17155000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9659000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11754000 USD
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5323000 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
17798000 USD
CY2021Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1412000 USD
CY2020Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
9562000 USD
CY2021Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
564000 USD
CY2020Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
9661000 USD
CY2021Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
5461000 USD
CY2020Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
4640000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
466711000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
492548000 USD
CY2021Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
16455000 USD
CY2020Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
9500000 USD
CY2021Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
6809000 USD
CY2020Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
28818000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
461961000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
532725000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1412926000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1400263000 USD
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1100000000 USD
CY2021Q3 us-gaap Convertible Debt
ConvertibleDebt
1078093000 USD
CY2020Q4 us-gaap Convertible Debt
ConvertibleDebt
1075145000 USD
CY2021Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1111812000 USD
CY2020Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1157804000 USD
CY2021Q3 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
11128000 USD
CY2021Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
133000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-183000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11178000 USD
CY2020Q3 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
-18295000 USD
CY2020Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
1878000 USD
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
20626000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-19665000 USD
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
-4953000 USD
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-799000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
26378000 USD
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
3798000 USD
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
13027000 USD
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
550000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9779000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
408742000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
476784000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1396465000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1408338000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
837001000 USD
CY2021Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
CY2020Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
7070000 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49026000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50169000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153372000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
142125000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36494000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
784803000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6182000 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
18333000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-36494000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
791873000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6182000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
855334000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
183214000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
181142000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182616000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180592000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
183214000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197674000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182616000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
194959000 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.63
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.39
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21055000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8265000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21055000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8439000 shares
CY2021Q3 bmrn Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
708800000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
63400000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
48200000 USD
CY2021Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
107700000 USD

Files In Submission

Name View Source Status
0001048477-21-000032-index-headers.html Edgar Link pending
0001048477-21-000032-index.html Edgar Link pending
0001048477-21-000032.txt Edgar Link pending
0001048477-21-000032-xbrl.zip Edgar Link pending
bmrn-20210930.htm Edgar Link pending
bmrn-20210930.xsd Edgar Link pending
bmrn-20210930_cal.xml Edgar Link unprocessable
bmrn-20210930_def.xml Edgar Link unprocessable
bmrn-20210930_htm.xml Edgar Link completed
bmrn-20210930_lab.xml Edgar Link unprocessable
bmrn-20210930_pre.xml Edgar Link unprocessable
exhibit311-30sep21x10q.htm Edgar Link pending
exhibit312-30sep21x10q.htm Edgar Link pending
exhibit321-30sep21x10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending